Sagent Pharmaceuticals Enters Ophthalmic Market with Launch of Travoprost Ophthalmic Solution 0.004%

Sagent Pharmaceuticals has announced its entry into the ophthalmic market with the launch of travoprost ophthalmic solution, USP 0.004%, marking the company’s first product offering in eye care.

First Ophthalmic Product Targets Elevated Intraocular Pressure

Travoprost is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, conditions that can lead to progressive vision loss if left untreated.

This product launch positions travoprost as the first entry in Sagent’s ophthalmic portfolio, with plans to expand the portfolio further over the coming year, according to the company.

Leadership Perspective on Market Expansion

“Expanding into the ophthalmic space marks a significant step in broadening our portfolio and reinforcing our trajectory of sustainable growth,” said Vishy Chebrol, PhD, CEO of Sagent Pharmaceuticals.

“We remain guided by our mission to improve patient outcomes, while leveraging our proven strengths in quality and reliability to ensure dependable access and long-term value.”

While travoprost is Sagent’s first ophthalmic product, the company currently offers a broad portfolio of over 100 injectable and specialty pharmaceutical products. These are used across hospitals, long-term care facilities, alternate care sites, and clinics, highlighting Sagent’s established role in the broader pharmaceutical landscape.